Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Intellectual property legal development expenses

Intellectual property legal development expenses at other companies

EyePoint, Inc. logo
EyePoint, Inc.EYPT
$224.5K-34.0%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$224.5K-34.0%
Adeia logo
AdeiaADEA
$5.33M-25.6%
International Business Machines logo
International Business MachinesIBM
$172M-32.0%
Clarivate logo
ClarivateCLVT
$12.5M-0.8%
Clarivate logo
ClarivateCLVT
$69.4M-5.8%

Segments

By segment

See full
Affordable Medicines$2M+1.2%
AvKARE$0

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept amrx:IntellectualPropertyLegalDevelopmentExpenses.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Gross profit334,508286,253654,621542,144
Selling, general and administrative148,722124,266287,582242,554
Research and development39,01747,96477,40088,004
Intellectual property legal development expenses2,0872,0173,6293,784
Acquisition costs7,60012,753
Restructuring and other charges5541,0241,2041,595
Charges (credit) related to legal matters, net8,057(390)8,751(390)
Other operating income(1,298)(8,239)(5,122)

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s intellectual property legal development expenses?
Amneal Pharmaceuticals, Inc. (AMRX) reported intellectual property legal development expenses of $2.09M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s intellectual property legal development expenses changed year-over-year?
Amneal Pharmaceuticals, Inc.'s intellectual property legal development expenses increased by 3.5% year-over-year, from $2.02M to $2.09M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s intellectual property legal development expenses?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s intellectual property legal development expenses has grown at a 20.5% compound annual growth rate (CAGR), from $4.36M to $7.63M.
What does intellectual property legal development expenses mean?
This metric represents the costs incurred by the company related to the legal protection, defense, and development of its intellectual property portfolio. It captures expenditures associated with patent filings, litigation to enforce proprietary rights, and legal strategies aimed at securing market exclusivity for pharmaceutical products. Monitoring these costs helps investors assess the company's investment in maintaining its competitive moat and the legal risks associated with its product pipeline.

Ask your AI about Amneal Pharmaceuticals, Inc.'s intellectual property legal development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude